Description

POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research[1][2]–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-protein/nucleotide metabolism–C72H102N22O18S2—-[1]S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.|[2]Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40(1):18-26.–934461-40-2–1627.85–99.60–C(C=1C=2C(N(C)C1)=CC=CC2)[C@H]3C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=4C=5C(NC4)=CC=CC5)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC6=CN=CN6)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(N[C@@H]([C@@H](C)O)C(N)=O)=O)CSSC[C@H](NC([C@H]([C@H](CC)C)NC(C)=O)=O)C(=O)N[C@@H](C(C)C)C(=O)N3–Metabolic Disease–DMSO : 100 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)–Complement System—-Immunology/Inflammation–Peptides